Progress of targeted immunotherapy in treatment of relapsed/refractory follicular lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 72-74, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-742756
ABSTRACT
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. The overall survival of FL is near 15 years. However, the survival would be significantly shortened in refractory, early-relapsed or transformed setting. The 60th American Society of Hematology (ASH) Annual Meeting reported several latest and optimal approaches to relapsed/refractory FL, with a focus on immune-based therapies and target agents for FL. This paper reviews and makes comments about these clinical trials.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS